Literature DB >> 27995469

A case of liver hemangioma with markedly reduced tumor size after metformin treatment: a case report.

Minoru Ono1, Koji Sawada2, Toshikatsu Okumura3.   

Abstract

A 52-year-old man with a 9-year history of hepatic hemangioma was treated with the anti-diabetic drug metformin, resulting in complete remission of the tumor. In 2006, a hemangioma with diameter of 20 × 25 mm was detected incidentally in the liver. The results of imaging studies including ultrasound (US), computed tomography (CT) and magnetic resonance imaging (MRI) were all compatible with that of hepatic hemangioma. The patient consequently underwent imaging annually from 2006 to 2015. The tumor size increased slightly, to 30 × 35 mm in 2012; however, the general tumor characteristics in imaging were not changed. Beginning May 2012, metformin (750 mg/day) was administered because of an increase in blood sugar and hemoglobin A1c levels. After the start of metformin treatment, the tumor size on US gradually decreased. Finally, in October 2015, the tumor was no longer detected. Dynamic CT study also demonstrated markedly reduced tumor size, with a decrease of 2-3 mm in diameter. These results indicate that metformin treatment strongly suppressed cell proliferation in liver hemangioma. The anti-angiogenic effect of metformin was indicated as a possible cause of the reduction in tumor size.

Entities:  

Keywords:  Anti-angiogenesis; Hepatic hemangioma; Metformin; mTORC1–VEGF pathway

Mesh:

Substances:

Year:  2016        PMID: 27995469     DOI: 10.1007/s12328-016-0705-0

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  29 in total

1.  Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC.

Authors:  Giovanni Blandino; Mariacristina Valerio; Mario Cioce; Federica Mori; Luca Casadei; Claudio Pulito; Andrea Sacconi; Francesca Biagioni; Giancarlo Cortese; Sergio Galanti; Cesare Manetti; Gennaro Citro; Paola Muti; Sabrina Strano
Journal:  Nat Commun       Date:  2012-05-29       Impact factor: 14.919

2.  Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells.

Authors:  Mahvash Zakikhani; Ryan Dowling; I George Fantus; Nahum Sonenberg; Michael Pollak
Journal:  Cancer Res       Date:  2006-10-23       Impact factor: 12.701

3.  Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1.

Authors:  Isaam Ben Sahra; Claire Regazzetti; Guillaume Robert; Kathiane Laurent; Yannick Le Marchand-Brustel; Patrick Auberger; Jean-François Tanti; Sophie Giorgetti-Peraldi; Frédéric Bost
Journal:  Cancer Res       Date:  2011-05-03       Impact factor: 12.701

4.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

5.  Metformin induces unique biological and molecular responses in triple negative breast cancer cells.

Authors:  Bolin Liu; Zeying Fan; Susan M Edgerton; Xin-Sheng Deng; Irina N Alimova; Stuart E Lind; Ann D Thor
Journal:  Cell Cycle       Date:  2009-07-21       Impact factor: 4.534

6.  Rapamycin inhibits proliferation of hemangioma endothelial cells by reducing HIF-1-dependent expression of VEGF.

Authors:  Damian Medici; Bjorn R Olsen
Journal:  PLoS One       Date:  2012-08-10       Impact factor: 3.240

Review 7.  Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review.

Authors:  Donna L White; Fasiha Kanwal; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2012-10-04       Impact factor: 11.382

8.  The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.

Authors:  I Ben Sahra; K Laurent; A Loubat; S Giorgetti-Peraldi; P Colosetti; P Auberger; J F Tanti; Y Le Marchand-Brustel; F Bost
Journal:  Oncogene       Date:  2008-01-21       Impact factor: 9.867

Review 9.  The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence.

Authors:  Hashem B El-Serag; Howard Hampel; Fariba Javadi
Journal:  Clin Gastroenterol Hepatol       Date:  2006-03       Impact factor: 11.382

Review 10.  Anti-tumor effects of metformin in animal models of hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  Juan Li; Pratika Y Hernanda; Wichor M Bramer; Maikel P Peppelenbosch; Judith van Luijk; Qiuwei Pan
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.